Get the Stockscreener App
10.49
15.95%
-1.99
After Hours:
10.47
-0.02
-0.19%
Emergent Biosolutions Inc stock is traded at $10.49, with a volume of 2.86M.
It is down -15.95% in the last 24 hours and up +14.64% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$12.48
Open:
$12.49
24h Volume:
2.86M
Relative Volume:
2.32
Market Cap:
$559.65M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.7107
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+8.26%
1M Performance:
+14.64%
6M Performance:
+104.09%
1Y Performance:
+15.02%
1-Day Range:
$10.16
$12.65
1-Week Range:
$9.21
$13.41
52-Week Range:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.49 | 655.45M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Will Emergent BioSolutions Inc. stock deliver consistent dividendsPortfolio Performance Summary & Short-Term High Return Ideas - newser.com
Emergent BioSolutions Inc.'s (NYSE:EBS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 29% Over Last Week - 富途牛牛
Will Emergent BioSolutions Inc. stock sustain high P E ratiosGap Down & Long-Term Investment Growth Plans - newser.com
Visual analytics tools that track Emergent BioSolutions Inc. performanceEarnings Risk Summary & Smart Swing Trading Alerts - newser.com
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesWeekly Stock Report & High Return Trade Guides - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is listed among top recommendations2025 Short Interest & Long-Term Safe Investment Plans - newser.com
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedQuarterly Profit Report & Reliable Intraday Trade Alerts - newser.com
Will Emergent BioSolutions Inc. stock justify high valuation2025 Major Catalysts & Real-Time Volume Spike Alerts - newser.com
Wolverine Asset Management LLC Raises Stock Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Is Emergent BioSolutions Inc. stock dividend yield sustainableJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Published on: 2025-11-03 02:38:18 - newser.com
How Emergent BioSolutions Inc. stock benefits from tech adoptionWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Published on: 2025-11-02 23:34:34 - newser.com
Combining price and volume data for Emergent BioSolutions Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Chart based exit strategy for Emergent BioSolutions Inc.2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com
Reversal indicators forming on Emergent BioSolutions Inc. stockQuarterly Profit Report & Reliable Trade Execution Plans - newser.com
Published on: 2025-11-02 23:01:50 - newser.com
Will Emergent BioSolutions Inc. stock return to pre crisis levelsMarket Sentiment Review & Fast Gain Stock Trading Tips - newser.com
Emergent BioSolutions (EBS) Is Up 28.1% After Strong Q3 Results and Raised 2025 Guidance Has the Bull Case Changed? - Yahoo Finance
Applying Wyckoff theory to Emergent BioSolutions Inc. stock2025 Top Gainers & Verified Entry Point Signals - newser.com
Published on: 2025-11-02 12:46:41 - newser.com
Published on: 2025-11-02 12:32:07 - newser.com
Will Emergent BioSolutions Inc. benefit from macro trendsJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Emergent BioSolutions Hits New 52-Week High of $13.41, Up 100.94% - Markets Mojo
Why Emergent BioSolutions Inc. stock remains resilient2025 Top Gainers & Daily Price Action Insights - newser.com
Why Emergent BioSolutions Inc. stock could rally in 2025July 2025 Fed Impact & Safe Investment Capital Preservation Plans - newser.com
Emergent Biosolutions (NYSE:EBS) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Is Emergent BioSolutions Inc. a candidate for recovery playVolume Spike & Reliable Price Action Trade Plans - newser.com
Emergent Biosolutions (NYSE:EBS) Hits New 52-Week HighHere's Why - MarketBeat
Published on: 2025-11-01 03:39:59 - newser.com
Published on: 2025-11-01 02:24:00 - newser.com
Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out? - sharewise.com
Will breakout in Emergent BioSolutions Inc. lead to full recoveryTreasury Yields & Advanced Swing Trade Entry Alerts - newser.com
Understanding Emergent BioSolutions Inc.’s price movementWeekly Market Report & Fast Moving Stock Watchlists - newser.com
Emergent BioSolutions’ Earnings Call Highlights Strong Growth - The Globe and Mail
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding - GlobeNewswire Inc.
Emergent Biosolutions (NYSE:EBS) Shares Gap Up After Strong Earnings - MarketBeat
Emergent BioSolutions Raises Full-Year Revenue Guidance - MSN
Why millennials buy Emergent BioSolutions Inc. (ER4) stockJuly 2025 Market Mood & Precise Buy Zone Tips - newser.com
Is Emergent BioSolutions Inc. stock resilient in recession scenarios2025 Pullback Review & Long Hold Capital Preservation Tips - newser.com
Analyzing Emergent BioSolutions Inc. with multi timeframe charts2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
What sentiment indicators say about Emergent BioSolutions Inc. stock2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.35%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):